Organ perfusion machines cost $250K+, locking out small transplant centers

Normothermic machine perfusion (NMP) can keep organs alive and functioning outside the body for hours longer than traditional cold storage on ice, dramatically expanding the radius from which a transplant center can accept organs and enabling assessment of marginal organs before transplanting them. But FDA-cleared devices from companies like TransMedics, OrganOx, and XVIVO cost over $250,000 per unit, with proprietary disposable cartridges adding thousands per use. Only large, high-volume transplant programs can amortize these costs. Smaller and rural programs—which serve patients who already face geographic barriers to transplant—cannot afford the technology and must continue declining organs with longer transport times. This creates a two-tier system: patients at major academic centers benefit from organs that would have been discarded, while patients at smaller centers die waiting. The organ discard rate for kidneys is already 34% nationally, and many of those discards are marginal organs that could be assessed and rehabilitated via perfusion. Researchers have started developing open-source, low-cost perfusion circuits (targeting under $75,000), but these are years from clinical use. The structural barrier is that the small number of FDA-cleared manufacturers face no price competition, and CMS reimbursement for perfusion technology has not kept pace with device costs.